Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

计划入组 19 人 · 首次发布于 2024 年 3 月 8 日

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

计划入组 12 人 · 首次发布于 2014 年 4 月 14 日

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

计划入组 85 人 · 首次发布于 2023 年 4 月 25 日

INR-302

GNR-084

RPR-114849

RNV LLC

United States

Rna Diagnostics, Inc.

Canada

RNA Pharma, LLC

United States

Boundless Bio Prioritizes BBI-355 and New ecDTx Program, Discontinues BBI-825 Development

Genedrive Completes PALOH-UK Recruitment: Nearly 6,000 Babies Tested for Antibiotic-Induced Hearing Loss Risk

Wave Life Sciences' RNA Editing Data Sparks Rally in RNA Therapy Stocks